AstraZeneca’s AZN first-quarter 2023 core earnings of 96 cents per American depositary share (ADS) beat the Zacks Consensus Estimate of 86 cents and our model estimate of 85 cents. Core earnings of $1 ...

Currently, the S&P 500 and many sectors are outperforming the healthcare sector, presenting an opportunity to explore assets within this sector during the current period of apathy towards it.

March 18 (Reuters) - Drugmaker AstraZeneca (AZN.L), opens new tab said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States from June, ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor Corp., AstraZeneca PLC ...

AstraZeneca (www.AstraZeneca.com) is pleased to announce its partnership with MYDAWA as part of our commitment to work towards a future where all people have access to sustainable healthcare solutions ...

AstraZeneca's (NASDAQ:AZN) stock is trading in the green premarket on Thursday after Q1 results beat estimates and the company reaffirmed its FY23 outlook. Core EPS grew +1%% at actual exchange rates ...